Drug Profile
Research programme: skin disorders therapeutics - AnGes
Latest Information Update: 03 Jan 2020
Price :
$50
*
At a glance
- Originator AnGes MG
- Developer AnGes
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 03 Jan 2020 AnGes MG is now called AnGes
- 21 May 2010 No development reported - Preclinical for Skin disorders in Japan (unspecified route)